Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Rimonabant for Improving Cognitive Impairment in Patients with Post‑COVID‑19 Syndrome: A Randomized, Placebo‑Controlled Trial

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on people who continue to have problems after recovering from a coronavirus infection, known as Post‑COVID‑19 syndrome. A common issue in this condition is difficulty thinking clearly, remembering, or concentrating, often described as “brain fog.” The medication being tested is an oral tablet containing rimonabant, a drug that works by blocking a specific receptor in the brain. Participants will receive either the rimonabant tablets or an inactive tablet, referred to as a placebo, so that researchers can compare the effects.

The main goal is to see whether rimonabant can improve cognitive performance compared with the placebo. After an initial screening visit, participants will take the study medication for several weeks, returning for a series of follow‑up visits where simple tests are performed. Cognitive ability will be measured with a short paper‑and‑pencil task called the Symbol Digit Modalities Test, which evaluates how quickly a person can match symbols to numbers. Physical endurance will be checked using the 6‑Minute Walk Test, and basic mobility will be assessed with the Timed Up and Go test, which records the time needed to stand up, walk a short distance, turn, and sit down again. Quality of life will also be recorded using a standard questionnaire known as the EQ‑5D‑5L.

Throughout the study, researchers will monitor participants for any side effects, check vital signs, and perform routine safety checks such as blood tests and an electrocardiogram. All information collected will be used only to determine whether the medication is safe and whether it helps improve thinking skills and overall well‑being in people with Post‑COVID‑19 syndrome.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline visit (v01)

    After joining the study, you will attend the first study visit. during this visit a series of assessments will be performed to record your current condition.

    You will complete the symbol digit modalities test, which measures how quickly you can match symbols with numbers. this test provides the baseline score for cognitive performance.

    You will answer questionnaires about cognitive fatigue, sleep quality, overall fatigue, brain fog, pain, mood, and quality of life.

    You will perform walking tests: a six‑minute walk to assess endurance, a ten‑meter walk to assess speed, and the timed up‑and‑go test to assess reaction time when starting to walk.

    A brief physical examination, blood draw, vital‑sign measurement, and an electrocardiogram will be done.

    You will receive a supply of study medication. the medication is either rimonabant 5 mg tablet or a matching placebo tablet, to be taken by mouth as instructed for the duration of the treatment period.

  2. Step 2

    Treatment visit 2 (v02)

    You will return for the second treatment visit. the same set of assessments performed at the baseline visit will be repeated, including the symbol digit modalities test, fatigue and sleep questionnaires, walking tests, mood scales, and physical examinations.

    The study medication will continue to be taken as instructed. any side effects or new health problems should be reported to the study staff.

  3. Step 3

    Treatment visit 3 (v03)

    The third treatment visit follows the same procedure as previous visits. cognitive testing, questionnaires, walking tests, and physical checks are repeated to monitor changes over time.

    You will keep taking the study medication and continue to report any adverse events.

  4. Step 4

    Treatment visit 4 (v04)

    The fourth treatment visit again includes the full set of cognitive and functional assessments. the purpose is to track progress while you are still receiving the medication.

    Continue the medication schedule and report any symptoms or concerns.

  5. Step 5

    Follow‑up visit (v05)

    The final visit occurs after the treatment period ends. all assessments performed at earlier visits are repeated to evaluate the overall effect of the medication.

    The study medication is discontinued after this visit.

    Final safety checks, including blood tests, vital signs, and electrocardiogram, are performed, and a summary of any adverse events is collected.

Who can join the trial?

9 criteria

  • Be between 18 and 75 years old, including the end numbers.
  • Have had COVID-19 infection at least 3 months before joining the study.
  • Be diagnosed with active Post‑COVID‑19 syndrome (PCS, also called Long COVID).
  • Have ongoing problems with memory or concentration that are caused by Long COVID.
  • Show signs of cognitive impairment (difficulty thinking, remembering, or focusing) when the study tests are done.
  • Be willing to complete all the study assessments that are required.
  • Be able to understand and speak Spanish.
  • Give written permission (signed consent) to take part in the study.
  • Have a Brain Fog Scale score of 47 or higher, indicating noticeable brain‑fog symptoms.

Who cannot join the trial?

15 criteria

  • Having a current or recent COVID-19 infection.
  • Having other illnesses that could explain the symptoms you are experiencing.
  • Having severe disease of the lungs, heart, liver, kidneys, or bones.
  • Having a body mass index (BMI) higher than 40 kg/m² (a measure of weight compared with height).
  • Being unable to walk or to attend the study visits.
  • Using substances or medicines that could affect memory or concentration.
  • Having major depression or severe anxiety diagnosed by a psychologist or psychiatrist (for example, a high score on standard questionnaires).
  • Taking medicines that could interact with the study drug.
  • Having a known allergy to rimonabant, the medication being tested.
  • Having participated in another clinical trial within the past month.
  • Being pregnant or breastfeeding.
  • Being able to become pregnant or father a child and not using reliable birth control.
  • Having a high risk of suicide.
  • Having severe mental health conditions such as major depression, severe anxiety, bipolar disorder, schizophrenia, psychotic disorders, a previous suicide attempt, or any condition that required psychiatric hospitalization.
  • Having neurological conditions (disorders of the brain or nerves) that could affect memory or concentration.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Rimonacetam is a pill taken by mouth that works by blocking a specific part of the brain called the CB1 receptor. By doing this, it may help improve thinking problems, memory, and concentration that some people experience after having COVID‑19. In the trial, participants received this medication to see if it can make their cognitive abilities better compared with not taking the active drug.

What is already known about the treatment

Rimonabant - Rimonabant is taken as an oral tablet, usually 2.5 mg, and is swallowed with water. It was once approved for treating obesity but was withdrawn from the market because of safety concerns, so it is now only used in research studies. In this trial it is being tested to help improve thinking problems in people who have post‑COVID‑19 syndrome. The drug works by blocking the CB1 receptor in the brain, which reduces the activity of the body’s natural cannabinoid system; it is classified as a cannabinoid‑receptor antagonist/inverse agonist.

Investigated diseases

Post-COVID-19 syndrome - Post-COVID-19 syndrome is a condition that occurs after a person has recovered from the acute phase of COVID-19. It is characterized by a range of symptoms that persist for weeks or months beyond the initial infection. Common problems include fatigue, difficulty concentrating, memory lapses, and sleep disturbances. Symptoms may fluctuate, with some days feeling better and others worse. The condition can affect people of any age, even those who had mild initial illness. Over time, many individuals experience gradual improvement, although some may have persistent issues.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-507870-42-00Protocol codeRIMOCOVID-1Estimated enrolment80 patients

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).